Drug intelligence / Profile preview

capecitabine + IMRT

Development stage: Unknown
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Oral, External Radiation

Overview

Capecitabine + IMRT is a combination therapy consisting of the oral fluoropyrimidine capecitabine administered concurrently with Intensity-Modulated Radiation Therapy (IMRT). Capecitabine is a prodrug that converts to 5-fluorouracil (5-FU) in tumor tissues, providing targeted cytotoxic effects. IMRT is an advanced radiation technique that delivers precise radiation doses to tumor areas while minimizing exposure to surrounding healthy tissues. This combination has been studied in various cancers including anal squamous cell carcinoma, gastric cancer, and head and neck cancers, showing favorable efficacy and toxicity profiles compared to other chemoradiation regimens.

Targets

TS (Thymidylate synthase)

Beyond the preview

Go deeper on capecitabine + IMRT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on capecitabine + IMRT.

Explore the full profile